Arrowstreet Capital
AVNS

Arrowstreet Capital’s Avanos Medical AVNS Stock Holding History

Arrowstreet Capital’s Portfolio AVNS Stock Details AVNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$167K Buy
+11,953
New +$161K ﹤0.01% 1784
2025
Q3 		– Sell
-28,703
Closed -$351K – 1857
2025
Q2 		$351K Sell
28,703
-22,505
-44% -$283K ﹤0.01% 1811
2025
Q1 		$734K Sell
51,208
-208,209
-80% -$3.25M ﹤0.01% 1543
2024
Q4 		$4.13M Sell
259,417
-195,514
-43% -$3.87M ﹤0.01% 1060
2024
Q3 		$10.9M Buy
454,931
+357,750
+368% +$8.18M 0.01% 723
2024
Q2 		$1.94M Sell
97,181
-134,179
-58% -$2.61M ﹤0.01% 1082
2024
Q1 		$4.61M Buy
231,360
+5,720
+3% +$111K ﹤0.01% 916
2023
Q4 		$5.06M Buy
+225,640
New +$4.66M 0.01% 746
2023
Q3 		– Sell
-169,440
Closed -$4.33M – 1250
2023
Q2 		$4.33M Sell
169,440
-343,405
-67% -$9.04M 0.01% 654
2023
Q1 		$15.3M Buy
512,845
+178,426
+53% +$5.18M 0.02% 461
2022
Q4 		$9.05M Buy
334,419
+156,702
+88% +$3.83M 0.01% 548
2022
Q3 		$3.87M Buy
177,717
+97,346
+121% +$2.54M 0.01% 715
2022
Q2 		$2.2M Sell
80,371
-68,871
-46% -$1.98M ﹤0.01% 756
2022
Q1 		$5M Buy
+149,242
New +$4.81M 0.01% 634
2021
Q3 		– Sell
-225,813
Closed -$8.21M – 1581
2021
Q2 		$8.21M Sell
225,813
-51,460
-19% -$2.13M 0.01% 902
2021
Q1 		$12.1M Buy
277,273
+95,525
+53% +$4.48M 0.02% 790
2020
Q4 		$8.34M Buy
+181,748
New +$7.56M 0.01% 956
2020
Q3 		– Sell
-96,317
Closed -$2.83M – 2321
2020
Q2 		$2.83M Buy
96,317
+81,617
+555% +$2.36M 0.01% 1312
2020
Q1 		$396K Buy
+14,700
New +$439K ﹤0.01% 1572
2016
Q4 		– Sell
-304,345
Closed -$10.5M – 1651
2016
Q3 		$10.5M Buy
+304,345
New +$10.7M 0.03% 433
2016
Q1 		– Sell
-281,965
Closed -$9.42M – 1331
2015
Q4 		$9.42M Sell
281,965
-86,790
-24% -$2.7M 0.04% 363
2015
Q3 		$10.5M Buy
368,755
+71,176
+24% +$2.48M 0.05% 336
2015
Q2 		$12.1M Sell
297,579
-140,765
-32% -$6.32M 0.07% 234
2015
Q1 		$21.6M Sell
438,344
-162,929
-27% -$7.55M 0.13% 176
2014
Q4 		$27.3M Buy
+601,273
New +$23.6M 0.16% 145

Other funds holding AVNS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Arrowstreet Capital's AVNS Position: Q1 2026 in Review

Arrowstreet Capital opened a new position in Avanos Medical (AVNS) in Q1 2026: 11,953 shares worth $167K. The stake represents ﹤0.01% of the portfolio and ranks #1784 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in AVNS as recently as Q2 2025.

Arrowstreet Capital first reported a position in AVNS in Q4 2014 and has held it in 25 quarters since. The position peaked at $27.3M in Q4 2014. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.

  • Arrowstreet Capital held 11,953 shares of Avanos Medical worth $167K as of Q1 2026.
  • Avanos Medical was a new Arrowstreet Capital position in Q1 2026.
  • Avanos Medical made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1784 holding.
  • Arrowstreet Capital first reported a position in Avanos Medical in Q4 2014 and has held it in 25 quarters since.
  • Arrowstreet Capital's Avanos Medical position peaked at $27.3M in Q4 2014.
  • 257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.